Axerion Therapeutics

Axerion Therapeutics, Inc. is a privately-held biotechnology company based in Connecticut, dedicated to developing innovative therapies for neurological diseases and injuries, including unmet medical needs such as Alzheimer's disease and spinal cord injury.Founded in New Haven, Axerion aims to develop and commercialize intellectual property licensed from the laboratory of Dr. Stephen Strittmatter at Yale University. Axerion’s proprietary technology platform includes blockers of β-amyloid (Aβ) oligomers that bind to the prion protein (PrP) on the surface of nerve cells as a new therapeutic target for Alzheimer's disease, and Nogo Receptor decoy proteins for restoring neurological function in spinal cord injury and other neurological disorders.